Condition: Hemophilia B · Sponsor: CSL Behring
The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.
This description comes directly from the study's public registry record.
Trial Registration Coordinator · 1-610-878-4697 · clinicaltrials@cslbehring.com
Always discuss trial participation with your own doctor first.
| University of California, San Diego (UCSD) | San Diego, California, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Hemophilia Center of Western Pennsylvania (HCWP) | Pittsburgh, Pennsylvania, United States | Recruiting |
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Recruiting |
| Royal Brisbane Hospital | Herston, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo | São Paulo, Brazil | Recruiting |
| UNICAMP Universidade Estadual de Campinas | São Paulo, Brazil | Recruiting |
| Specialized Hospital for Active Treatment of Hematological Diseases | Sofia, Bulgaria | Recruiting |
| McMaster University - Hamilton | Hamilton, Ontario, Canada | Recruiting |
| Queen Mary Hospital | Hong Kong, Hong Kong | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06003387